Abbott distributes both Ozempic and Wegovy in India, but this is the first time it is marketing the product under its brandname, an industry-insider pointed out.
Multinational Abbott is partnering with Novo Nordisk India to commercialise Extensior, as a second brand of Ozempic, for treating people living with type 2 diabetes.
Novo Nordisk had in December brought its globally popular Ozempic, reportedly the world’s most prescribed GLP-1 RA (receptor agonist) molecule, to India.
Key partnership
Separately, it had also inked a partnership with Emcure for a second brand of its weightloss product Wegovy.
This segment is seeing increased activity as a patent on semaglutide, the active ingredient in Ozempic and Wegovy, lose patent protection later next month in many markets, including India.
Abbott distributes both Ozempic and Wegovy in India, but this is the first time it is marketing the product under its brandname, an industry-insider pointed out.
While details on how it will be priced are not available, it will be pegged possibly lower than the originator’s price, the industry-source told businessline, adding that prices could drop further, as the patent on semaglutide expires.
The product will be available in a FlexTouch pen — a once-weekly device that provides precise dosing in 0.25 mg, 0.5 mg and 1 mg dose strengths, Abbott said.
Novo’s weekly price, announced at launch, were 0.25mg at ₹2,200, 0.5mg at ₹2,542 and 1mg at ₹2,794.
Risk reduction
Semaglutide has also demonstrated powerful HbA1c reduction, compelling weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes, it added.
Kartik Rajendran, Managing Director, Abbott India Limited said, “The launch of Extensior builds on Abbott’s longstanding focus on holistic diabetes management — from medicines to diagnostics, and from continuous glucose monitoring to diabetes‑specific nutrition. Developed and manufactured by Novo Nordisk, this brand will be commercialised by Abbott,” it added.
Vikrant Shrotriya, Managing Director, Novo Nordisk India said, “Semaglutide represents one of the most significant scientific advancements in diabetes care in recent decades. It has changed the way type 2 diabetes is managed, offering meaningful improvements in metabolic, renal and cardiovascular health.”
India is home to more than 100 million individuals inwho live with diabetes, second only to China. The national diabetes‑related expenditure is over $9.8 billion (₹88,000+crore), the note said.
Published on February 27, 2026